Member Info for Ophidian

Click it yourself moron on investor meet

Typically, it means that they have had more positions opened in one direction (long) meaning they have to buy shares to cover the bets and the number of shares they have to have has now reached their internal upper limit (typically close to when they would have to TR1 a holding - which they don't want to).

They typically balance long bets vs. short bets but once a load of positions are all opened "Long" that is no longer possible and they have to buy in the market to over them

Also gone close only on the SB platforms

Having spent 30 years in Big Pharma R&D I assure you it is your comment that is bizarre in this context

Big Pharma don't like diagnostics - they prefer them to be independent. My view - todays appointment is about offloading the diagnostic as the Big Pharma interest won't want it

McCarthy recently described P140 as a “Humira-type opportunity” in his video interview emphasizing its potential to become a blockbuster autoimmune therapy. But why choose Humira - there are plenty of other possibly better examples he could have chosen.

Is he in talks with AbbVie ?

If not the top candidates for P140 (imo) are:

Roche: Already dominant in lupus (Benlysta via GSK partnership) and autoimmune diagnostics. P140’s diagnostic-linked targeting could complement Roche’s precision medicine strategy.

Bristol Myers Squibb (BMS): Strong in immunology (e.g. Orencia, Zeposia) and has shown interest in novel mechanisms that avoid broad immunosuppression.

Sanofi: Active in CIDP and inflammatory diseases, with a history of acquiring innovative biologics (e.g. Principia Biopharma for BTK inhibitors).

But his choice of example makes me wonder if it's not just AbbVie

Chart now looks primed - reverse head and shoulders signals 23p+ from here. Perfect ABC retrace to find both the Fib line and the support line.

It's quite crazy. Spend £260 today get £350 back.

Madness

Reverse H&S forming - visit 39/40 again then nice move up coming

Under the UK Takeover Code, Form 8 (DD) is generally required for Public Dealing Disclosures when there are dealings in relevant securities by a party to an offer or a person acting in concert. If no such dealings have occurred, the form may not be required, even if discussions are taking place before an offer is made.

However, the Takeover Panel may require disclosures for transparency, depending on the circumstances. For example, if the discussions are public knowledge or if there are significant market movements, the Panel might request disclosures to ensure a fair and orderly market.

Do yourself a favour and take half an hour off from here and watch this:

https://www.youtube.com/watch?v=v5kstO1R2vA&ab_channel=StateofMedTech

spouting bull**** about doxorubicin pharmacokinetics versus ava6000 has been the best sport yet in the litany of how stupid am i posts from the egg. i particularly loved the doxorubicin stays around longer line - couldn't make it up - oh hang on that's exactly what he did.

so to help: doxorubicin has a very complex multiphasic pharmacokinetic profile. the initial distribution half life is about 5 minutes after which time more than 50% is locked up in fatty tissues and no good at all for tumour destruction. ava6000 on the other hand sticks around in the blood for hours (4-6) all the time depositing doxorubicin in the tme as it circulates. the elimination half life of cleaved doxorubicin from ava6000 and that of straight dosed doxorubicin are of course exactly the same since like it or not dox is dox.

and as far as the elimination half life and the metabolite profile goes it's all a pointless crock of nonsense because what is important isn't what is eliminated as that can do no good at all - it's what is not eliminated but is intercalated in the tumour cells and off course only doxorubicin in the tme is intercalated into tumour cells and the surrounding stroma. for those poor souls being dosed with straight dox - what isn't eliminated through normal metabolic pathways is more than 98% intercalating with healthy cells not cancerous ones.

just a tiny bit of research can eliminate a whole day of reading utter tosh on here - i suggest people try it

@red_hornet - I said it could go up safely now the gap is closed (i.e. without the worry it targets the gap on the next retrace). I did no say it would only go up now or imply it would take off either, simply that the next move up (whenever it comes - as I believe it must) is much less likely imo to retrace back to that gap.

At 1.3p safely up now

Peculiar language in the RNS

" is anticipated being awarded a grant of up to EUR 300,000 under the EU Just Transition Fund"

so is it awarded or isn't it ? Perhaps PHE will wait to RNS something definite rather than anticipated

Thx 15Lives - appreciate the reply

Hi Zodiac - no I am already bought in. My calcs say that the retrace AFTER the next move up should complete ABOVE 1.3, but with the gap at 1.3 still there, then it is very likely that that retrace would go deeper to find it especially as it sits about right for a standard Fib line. I would rather see the share price just move according to usual patterns without delays to gap fill that is all.

Also a retest of 1.3 and gap fill now is also nicely hitting the 50% Fib for this as a Wave 4 which makes the next move up somewhat predictable (which I prefer)

It would still be nice to see it close the gap at 1.3p before then moving up (safely)

"National H2 expects to finalise these agreements by the end of Q2 CY23. Following this, the Company will immediately begin seeking a planned listing on a major exchange to finance the large-scale opportunity it has at hand."

This from the Media section of their website. Does anyone know the current state of this aspiration ?

Thx